Observational studyCardiovascular diabetology2026
Association between insulin resistance-related indices and the risk of recurrence after catheter ablation in patients with nonvalvular atrial fibrillation.
Observational study in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInsulin resistance (IR) is closely associated with the development and recurrence of atrial fibrillation (AF). Several non-insulin-based surrogate markers of insulin resistance, including the triglyceride-glucose index (TyG), triglyceride-glucose-body mass index (TyG-BMI), metabolic score for insulin resistance (METS-IR), triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C), estimated glucose disposal rate (eGDR), and C-reactive protein-triglyceride-glucose index (CTI), can be calculated from routine clinical biomarkers. However, the value of these indices in predicting recurrence after catheter ablation for AF remains unclear. In particular, CTI, a novel marker integrating inflammatory and metabolic status, has not been fully explored for its potential role in predicting post-ablation AF recurrence. This study aimed to systematically evaluate the association and predictive performance of six insulin resistance surrogate markers for AF recurrence after catheter ablation.
methodsThis retrospective two-center cohort study included 590 patients with nonvalvular AF who underwent first-time catheter ablation between January 2022 and March 2025. Six IR surrogate indices were calculated, and AF recurrence within 1 year was defined as the primary endpoint. Multivariable Cox regression, Kaplan-Meier analysis, restricted cubic spline (RCS) analysis, C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to assess associations and predictive value.
resultsDuring 1-year follow-up, 167 patients experienced recurrence (28.31%). Multivariable Cox analysis showed that lower eGDR and higher TyG, TyG-BMI, METS-IR, and CTI were associated with increased recurrence risk, with more stable associations observed for eGDR, TyG-BMI, METS-IR, and CTI. Kaplan-Meier and RCS analyses further supported stratified differences and exposure-response relationships for some indices. For predictive performance, eGDR showed the most favorable overall performance, while CTI, TyG-BMI, and METS-IR also provided incremental predictive value. TyG and TG/HDL-C showed relatively limited incremental value. After false discovery rate correction, subgroup analyses showed generally consistent results.
conclusionAmong the six IR surrogate indices, eGDR, CTI, TyG-BMI, and METS-IR were associated with AF recurrence after catheter ablation. eGDR showed the most favorable overall predictive performance. These indices may serve as adjunctive markers for post-ablation recurrence risk stratification, although prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.